Fulcrum and Slate Medicines sign merger agreement
Tue, August 18, 2026 at 11:56 AM GMT+3 2 min read
Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m private placement financing from a syndicate of healthcare investors.
The combined organisation, which will operate as Slate Medicines, is expected to be listed on Nasdaq under the "SLTE" ticker symbol.
Following completion of the merger, the new entity will focus on developing Slate's pipeline of migraine treatments, with SLTE-1009 as its lead candidate.
This clinical-stage subcutaneous anti- pituitary adenylate cyclase-activating peptide / vasoactive intestinal peptide (PACAP/VIP) monoclonal antibody is intended for the prevention of migraine and other headache disorders.
The financing is expected to support operations through 2029, enabling progress of SLTE-1009 through Phase I studies in healthy volunteers and a Phase II dose-range finding study in patients with migraine.
Also in development is SLTE-2100, a bispecific antibody targeting PACAP/VIP and calcitonin gene-related peptide (CGRP), which remains in the lead optimisation stage.
SLTE-2100 is scheduled to enter clinical trials in the second half of 2027 and has secured funding for a Phase IIa study in migraine.
The transaction, unanimously supported by the boards of both companies, is targeted to close in the fourth quarter of 2026, pending regulatory and shareholder approvals, as well as satisfaction or waiver of customary closing conditions.
Upon completion, pre-merger Fulcrum stockholders are expected to own 5% of the new company while pre-merger Slate stockholders and pre-closing financing investors are expected to hold 95%.
Fulcrum is anticipated to contribute net cash of nearly $20.3m and issue a cash dividend estimated at $270m, to be paid immediately prior to closing, to Fulcrum stockholders.
Slate Medicines CEO Gregory Oakes will lead the merged entity.
Oakes said: "Migraine remains one of the most prevalent and disabling neurological diseases, yet millions of patients continue to be underserved by existing therapies.
"This merger and the related financing are expected to provide the resources to advance SLTE-1009, along with the rest of our pipeline, through potentially meaningful clinical milestones."
Slate's management team includes president and chief operating officer Neil Buckley, chief medical officer Dr Roger Cady, and chief financial officer John Umstead.
The new company's board of directors will include representatives from RA Capital Management, Forbion, Foresite Capital, and a former executive of Verona Pharma.
"Fulcrum and Slate Medicines sign merger agreement" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.